Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The matrix below pairs the five most common 2026 research objectives with the compound whose published Phase 2/3 data most directly answers it, anchored to SURMOUNT-1 (tirzepatide), STEP 1 (semaglutide), and Jastreboff et al
Redner A, Grabowski E, Al-Katib A, Andreeff M
Keep reading Published on: November 19, 2025 KathyCare A commitment to yearly lung cancer screening A cancer survivor for more than a decade, Kathy said regular lung cancer screenings were the key to her survival
Compiled from each state's Medicaid PDL plus the dominant MCO formularies
US$ 23.10
US$ 28.08
US$ 20.23
